EU drug regulator recommends authorizing vaccine for monkeypox
July 22, 2022, 4:31 pm

EU drug regulator recommends authorizing vaccine for monkeypox

Monkeypox is caused by monkeypox viruses, a type of Orthopoxvirus. Of the 2-types in humans, the West African type causes a less severe disease than the Central African (Congo Basin) type. It may spread from handling bushmeat, animal bites or scratches, body fluids, contaminated objects, or other close contact with an infected person - Photo: Twitter

The European Medicines Agency said Friday (July 22) that the smallpox vaccine made by Bavarian Nordic should also be authorized against monkeypox, as the outbreak of the once-rare disease continues to sicken people across the continent, the Alarabiya English reported, citing the Associated Press.

The European Union drug regulator said its recommendation was based on animal studies that suggest the vaccine protects non-human primates from monkeypox.

It is up to the EU’s executive arm, the European Commission, to formally approve the vaccine based on the EMA’s recommendation.

The EMA said: “To confirm the effectiveness of the vaccine against monkeypox, the company will collect data from an observational study that will be carried out during the ongoing monkeypox outbreak in Europe.”

It added that the vaccine’s safety profile was “favorable” and the benefits of its use during the ongoing monkeypox outbreak outweighed the risks, noting mostly mild to moderate side effects.

Monkeypox is an infectious viral disease that can occur in both humans and some other animals. Symptoms include fever, swollen lymph nodes, and a rash that forms blisters and then crusts over. The time from exposure to onset of symptoms ranges from 5-to-21 days. The duration of symptoms is typically 2 to 4 weeks - Photo: Twitter

The vaccine, known as Imvanex in Europe but sold as Jynneos in the United States, was already cleared for use against monkeypox by American regulators.

Of the more than 15,000 monkeypox cases reported worldwide, nearly 70 percent are in Europe, with more than 30 countries across the continent affected. Doses of the Bavarian Nordic vaccine are extremely limited.

WHO to decide on sounding highest alarm on monkeypox
Most of the world’s supply has already been bought by countries and regions including Britain, Canada, the EU and the US.

None have gone to Africa, where a more severe version of monkeypox has killed dozens of people. No monkeypox deaths have been reported in rich countries.

People who catch monkeypox often experience symptoms that include fever, body aches, a rash and lesions; most recover within weeks without needing medical attention.

WHO to hold monkeypox emergency meeting on July 21

Authorities in numerous countries, including Britain, Germany and the US, have offered the vaccine to health workers and those at high risk of being infected by monkeypox.

In the US, soaring demand for the monkeypox vaccine caused the appointment system to crash in New York City, one of many places where supplies have run out almost immediately after they arrived.

Source: alarabiyaenglish

Saudi police arrest citizen who helped non-Muslim journalist use path to Makkah Britain has already paid £120 million for stalled Rwanda deal

BENEFIT, the Kingdom’s innovator and leading company in Fintech and electronic financial transactions service, has sponsored the BuildHer CityHack 2025 Hackathon, a two-day event spearheaded by the College of Engineering and Technology at the Royal University for Women (RUW).
Aimed at secondary school students, the event brought together a distinguished group of academic professionals and technology experts to mentor and inspire young participants.
More than 100 high school students from across the Kingdom of Bahrain took part in the hackathon, which featured an intensive programme of training workshops and hands-on sessions. These activities were tailored to enhance participants’ critical thinking, collaborative problem-solving, and team-building capabilities, while also encouraging the development of practical and sustainable solutions to contemporary challenges using modern technological tools.
BENEFIT’s Chief Executive Mr. Abdulwahed AlJanahi, commented: “Our support for this educational hackathon reflects our long-term strategic vision to nurture the talents of emerging national youth and empower the next generation of accomplished female leaders in technology. By fostering creativity and innovation, we aim to contribute meaningfully to Bahrain’s comprehensive development goals and align with the aspirations outlined in the Kingdom’s Vision 2030—an ambition in which BENEFIT plays a central role.”
Professor Riyadh Yousif Hamzah, President of the Royal University for Women, commented: “This initiative reflects our commitment to advancing women in STEM fields. We're cultivating a generation of creative, solution-driven female leaders who will drive national development. Our partnership with BENEFIT exemplifies the powerful synergy between academia and private sector in supporting educational innovation.”
Hanan Abdulla Hasan, Senior Manager, PR & Communication at BENEFIT, said: “We are honoured to collaborate with RUW in supporting this remarkable technology-focused event. It highlights our commitment to social responsibility, and our ongoing efforts to enhance the digital and innovation capabilities of young Bahraini women and foster their ability to harness technological tools in the service of a smarter, more sustainable future.”
For his part, Dr. Humam ElAgha, Acting Dean of the College of Engineering and Technology at the University, said: “BuildHer CityHack 2025 embodies our hands-on approach to education. By tackling real-world problems through creative thinking and sustainable solutions, we're preparing women to thrive in the knowledge economy – a cornerstone of the University's vision.”